Expertise in
13
conditions

Dr. Nasfat Shehadeh

Hematology | Oncology
Oncology Specialists Of Charlotte PA
2711 Randolph Rd Ste 400, 
Charlotte, NC 
Offers Telehealth
Expertise in
13
conditions
Oncology Specialists Of Charlotte PA
2711 Randolph Rd Ste 400, 
Charlotte, NC 

Overview

Nasfat Shehadeh is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina.

Dr. Shehadeh is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Stomach Cancer, Pancreatic Cancer, Pleuropulmonary Blastoma, Familial Pancreatic Cancer, and Bone Marrow Aspiration.

He is actively involved in clinical research, participating in 27 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in SC

Hospital Affiliations

Novant Health Mint Hill Medical Center
Novant Health Huntersville Medical Center
Atrium Health Pineville
Novant Health Presbyterian Medical Center
Novant Health Matthews Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Oncology Specialists of Charlotte PA
2711 Randolph Rd Ste 400, Charlotte, NC 28207

Additional Areas of Focus

Dr. Shehadeh has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
17
conditions
Dr. Ruben A. Mesa
Hematology | Oncology
Expertise in
17
conditions
Dr. Ruben A. Mesa
Hematology | Oncology

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
 (1.4 miles away)
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Mesa is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is board certified in American Board Of Internal Medicine, Hematology. Dr. Mesa is currently accepting new patients.

Expertise in
11
conditions
Dr. Manisha Bhutani
Hematology | Oncology
Expertise in
11
conditions
Dr. Manisha Bhutani
Hematology | Oncology

Atrium Health Levine Cancer Institute (Hematology)

1021 Morehead Medical Drive, Building 2, Suite 60201, 
Charlotte, NC 
 (1.4 miles away)
980-442-4363
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manisha Bhutani is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Bhutani is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhutani is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine, Hematology. Dr. Bhutani is currently accepting new patients.

Expertise in
7
conditions
Dr. Ifeyinwa Osunkwo
Hematology | Oncology
Expertise in
7
conditions
Dr. Ifeyinwa Osunkwo
Hematology | Oncology

Office

1021 Morehead Medical Dr, 
Charlotte, NC 
 (1.5 miles away)
980-442-2000
Languages Spoken:
English
See accepted insurances

Ifeyinwa Osunkwo is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Osunkwo is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Frequently Asked Questions about Dr. Nasfat Shehadeh

How do I make an appointment with Dr. Nasfat Shehadeh?

You can book an appointment with Dr. Nasfat Shehadeh by calling their office at 704-342-1900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nasfat Shehadeh a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nasfat Shehadeh is classified as an Advanced expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nasfat Shehadeh specialize in?

While Dr. Nasfat Shehadeh is a Hematology, they have specific expertise in Stomach Cancer, Pancreatic Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Nasfat Shehadeh accept my insurance?

Dr. Nasfat Shehadeh accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 704-342-1900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shehadeh's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 93 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile